Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy

• Published in: Biomedicine & pharmacotherapy 2023-09, Vol.165, p.115174-115174, Article 115174
• Main Authors: Krajcer, Aleksandra, Grzywna, Ewelina, Lewandowska-Łańcucka, Joanna
• Format: Article
• Language: English
• Subjects: Blood-brain- barrier; Drug delivery systems; Glioblastoma; Temozolomide
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115174

Glioblastoma (GBL) is the most common (60–70% of primary brain tumours) and the most malignant of the glial tumours. Although current therapies remain palliative, they have been proven to prolong overall survival. Within an optimal treatment regimen (incl. surgical resection, radiation therapy, and chemotherapy) temozolomide as the current anti-GBL first-line chemotherapeutic has increased the median overall survival to 14–15 months, and the percentage of patients alive at two years has been reported to rise from 10.4% to 26.5%. Though, the effectiveness of temozolomide chemotherapy is limited by the serious systemic, dose-related side effects. Therefore, the ponderation regarding novel treatment methods along with innovative formulations is crucial to emerging the therapeutic potential of the widely used drug simultaneously reducing the drawbacks of its use. Herein the complex temozolomide application restrictions present at different levels of therapy as well as, the currently proposed strategies aimed at reducing those limitations are demonstrated. Approaches increasing the efficacy of anti-GBL treatment are addressed. Our paper is focused on the most recent developments in the field of nano/biomaterials-based systems for temozolomide delivery and their functionalization towards more effective blood-brain-barrier crossing and/or tumour targeting. Appropriate designing accounting for the physical and chemical features of formulations along with distinct routes of administration is also discussed. In addition, considering the multiple resistance mechanisms, the molecular heterogeneity and the evolution of tumour the purposely selected delivery methods, the combined therapeutic approaches and specifically focused on GBL cells therapies are reviewed. [Display omitted] •Strategies increasing the efficacy of brain glioma TMZ therapy are reviewed.•Nanocarriers towards the effective BBB crossing play a key role in anti-GBL therapy.•Various routes of TMZ administration are also a strategy for GBL treatment.•The multi-antigen targeting is the promising approach for personalized therapy.•The combined therapies are significant future prospects for GBL treatment.